Hopp til hovedinnhold

Fingolimod

Sist oppdatert: Sist revidert:
Sist revidert av:
  1. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362: 387-401.
  2. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10: 520-9.
  3. Montalban X, Comi G, Antel J, O'Connor P, de Vera A, Cremer M, Sfikas N, von Rosenstiel P, Kappos L. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. J Neurol. 2015 Sep 4 . pmid:26338810 PubMed  
  4. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2015 Jun 25 . pmid:26111826 PubMed  
  5. Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015 Apr 14;84(15):1582-91 . pmid:25795646 PubMed  
  6. Gyang T et al. Fingolimod-associated PML in a patient with prior immunosuppression. Neurolgy 2016; May 10: 143-1845.
  7. Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci 2015; 22: 598-600. pmid:25523125 PubMed  
  8. Pilz G, Harrer A, Wipfler P, Oppermann K, Sellner J, Fazekas F, Trinka E, Kraus J.. Tumefactive MS lesions under fingolimod: a case report and literature review.. Neurology 2013; Nov 5;81(19):: 1654-8. pmid:24097813 PubMed  
  9. Castillo-Trivino T, Lopetegui I, Alarcón-Duque JA, López de Munain A, Olascoaga J. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015 Aug;86(8):931-2 . pmid:25835036 PubMed  
  10. Lutz Achtnichts, MD; Otilia Obreja, MD, PhD; Anna Conen, MD; Christoph A. Fux, MD; Krassen Nedeltchev, MD. Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod. JAMA Neurol. 2015 Oct 1;72(10):1203-5 . pmid:26457631 PubMed  
  11. Huang D. Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology. 2015 Sep 15;85(11):1001-3 . pmid:26291283 PubMed  
  12. Pfender N, Jelcic I, Linnebank M, Schwarz U, Martin R. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis. Neurology. 2015 Jun 9;84(23):2377-8 . pmid:25957334 PubMed  
  13. Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, Uitdehaag BMJ. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.Neurology. 2017 Aug 29;89(9):970-972. PMID: 28768850 PubMed  
  14. Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann Neurol 2020. pmid:32056253 PubMed  
  15. Hatcher SE1, Waubant E1, Nourbakhsh B1, Crabtree-Hartman E1, Graves JS1.. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. JAMA Neurol. 2016 Jul 1;73(7):790-4 . pmid:27135594 PubMed  
  16. Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology 2014; 23: 2153-7. pmid:25361781 PubMed  
  17. Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015; 72: 31-9. pmid:25419615 PubMed  
  18. Tyler KL. Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug. JAMA Neurol 2015; 72: 10-3. pmid:25420159 PubMed  
  19. Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, Keil A, Bijarnia M, Singh A, von Rosenstiel P. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology 2015; 84: 872-9. pmid:25636714 PubMed  
  • Øivind Fredvik Torkildsen, spesialist i nevrologi, professor PhD
  • Lars Bø, spesialist i nevrologi, professor dr med
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med

Tidligere fagmedarbeidere

  • Kjell-Morten Myhr, spesialist i nevrologi, professor dr med